Table of Contents Table of Contents
Previous Page  84 / 86 Next Page
Information
Show Menu
Previous Page 84 / 86 Next Page
Page Background

82

NCCN Guidelines for Patients

®

Nierenkrebs, Version 1.2015

Inhalt

Inhalt

Aktive Überwachung

30, 34, 44–46

Angiogenese

35, 55

Bildgebende Untersuchung

14, 16–18, 21, 22, 24, 25,

31, 34, 46–51, 56, 57

Biopsie

21, 22, 46, 48, 49

Blutuntersuchung

18, 19, 46, 48–51, 56, 57

Chirurgischer Eingriff, Operation

21, 30–34, 39, 40, 44,

45, 48–55, 59, 64

Computertomografie (CT)

16, 17, 21, 24, 25, 34, 46,

48–51, 56, 57

Gerota-Faszie

6, 7, 11, 26, 27, 52

Gezielte Therapie

35–38, 40, 55, 58, 59

Immuntherapie

35, 37, 40, 55, 58

Karzinom

4, 10, 12

Klarzelliges NZK

21, 22, 54, 55, 57, 58

Krebsstadium

24, 27, 28, 43, 50–52, 62

Magnetresonanz-Tomografie (MRT)

17, 25, 34, 46,

48–51, 56, 57

Metastasektomie

32, 52, 53, 56, 57

Nachsorgeuntersuchungen

47–51, 53, 55–57

Nebenniere

6, 7, 11, 24, 26, 27, 31, 40, 44, 50

Nebenwirkung, Begleiterscheinung

16, 31, 32, 34–40,

45, 48, 55–59, 63

Nicht-klarzelliges NZK

54, 55, 57

Nierenfunktion

17, 31, 32, 44, 48, 51, 56

Nierenvene

8, 26, 31

Partielle Nephrektomie

30, 31, 33, 40, 44, 45, 48, 49

Primärbehandlung

30, 38, 40, 44, 45, 50–52

Primärbehandlung

54, 55, 57, 58

Radikale Nephrektomie

31–33, 40, 44, 45, 48–50

Stadienbestimmung

23–28, 46, 49, 51, 56

Thermische Ablation

34, 44, 45, 48, 49

Tyrosinkinase-Inhibitor bzw. -Hemmer (TKI)

36, 55, 58

Unterstützende Behandlung

38, 40, 54, 55, 58, 59

Vena cava

7, 8, 25, 26, 31

Zytokin-Therapie

37, 40, 55, 58

Zytoreduktive Nephrektomie

32, 52, 53